Targretin® (bexarotene) capsules and gel are used to treat the skin problems arising from a disease called cutaneous T-cell lymphoma, or CTCL, in patients who have not responded well to other treatments. Your healthcare provider must supervise the use of Targretin.
IMPORTANT SAFETY INFORMATION INCLUDING PREGNANCY BOXED WARNING
What are the most important things I should know about Targretin?
Do not take Targretin capsules or use Targretin gel if you are pregnant or if you plan to become pregnant
- Targretin may harm your fetus (unborn baby). You should contact your healthcare provider immediately if you believe or suspect you are pregnant while being treated with Targretin, and until one month after you stop treatment with Targretin.
- If you are capable of becoming pregnant, you must have a pregnancy test, within one week before starting Targretin therapy and monthly while you are being treated with Targretin, confirming you are not pregnant.
- You must use effective contraception (birth control) continuously starting one month before starting treatment with Targretin until one month after you stop treatment with Targretin. It is strongly recommended that two reliable forms of contraception be used together. At least one of these two forms of contraception should include condoms, diaphragms, cervical caps, IUDs, or spermicides.
- If you are male and your partner is pregnant or capable of becoming pregnant, you should discuss with your healthcare provider the precautions you should take.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/medwatch or call 1-800-FDA-1088.
This is not all the safety information you need to know about Targretin. Please click here for full Prescribing Information for Targretin capsules, including Patient’s Instructions for Use. Please click here for full Prescribing Information for Targretin gel, including Patient’s Instructions for Use.